ESMO 2023: aanbevolen abstracten van studies bij longkanker door oncologen en medisch specialisten

Afgelopen week was er in Madrid ESMO 2023. Hier een aantal aanbevolen abstracten door vooraanstaande oncologen gerelateerd aan longkanker.

De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2023 gaat kunt u via de nummers vooraf aan de titels van de abstracten deze vinden.

Aanbevolen abstracten door Dr. Jean-Yves Douillard:

Friday, October 20, 2023
14:00–15:45 CEST; Proffered Paper Session
Non-Metastatic NSCLC and Other Thoracic Malignancies

LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JD Spicer

1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. MM Awad

Friday, October 20, 2023
16:00–17:30 CEST; Proffered Paper Session
NSCLC, Metastatic

LBA63 SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC). H Borghaei

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. MC Garassino

Saturday, October 21, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 1

LBA1 CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC. T Cascone

LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). BJ Solomon

LBA4 Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC. HHF Loong

LBA5 Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study. N Girard

Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 3

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01. AE Lisberg

LBA14 Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial. BC Cho

ESMO 2023, longkanker, aanbevolen abstracten, oncologen, medisch specialisten